Saxon Interests Inc. Acquires Shares of 9,420 Kura Oncology, Inc. (NASDAQ:KURA)

Saxon Interests Inc. purchased a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 9,420 shares of the company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of KURA. BVF Inc. IL increased its position in shares of Kura Oncology by 9.5% during the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after buying an additional 642,245 shares during the period. Verition Fund Management LLC bought a new position in shares of Kura Oncology in the fourth quarter worth approximately $6,695,000. Vanguard Group Inc. increased its position in shares of Kura Oncology by 7.5% in the third quarter. Vanguard Group Inc. now owns 3,924,448 shares of the company’s stock worth $35,791,000 after purchasing an additional 275,173 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Kura Oncology by 10.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock worth $28,785,000 after purchasing an additional 197,530 shares during the last quarter. Finally, Walleye Capital LLC increased its position in shares of Kura Oncology by 220.4% in the third quarter. Walleye Capital LLC now owns 264,893 shares of the company’s stock worth $2,416,000 after purchasing an additional 182,221 shares during the last quarter.

Kura Oncology Stock Performance

Shares of KURA stock opened at $20.58 on Wednesday. The stock has a fifty day moving average of $20.91 and a 200 day moving average of $19.51. Kura Oncology, Inc. has a 52 week low of $7.41 and a 52 week high of $24.17. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -9.48 and a beta of 0.88. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). During the same period in the prior year, the firm earned ($0.50) earnings per share. The company’s revenue was up .0% compared to the same quarter last year. As a group, research analysts expect that Kura Oncology, Inc. will post -2.56 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Teresa Brophy Bair sold 2,615 shares of Kura Oncology stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $22.15, for a total value of $57,922.25. Following the completion of the sale, the insider now directly owns 68,979 shares in the company, valued at approximately $1,527,884.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

KURA has been the topic of several research analyst reports. Wedbush restated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Friday, May 3rd. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, June 24th. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $28.36.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.